HOME ABOUT ▾ library contact order ABOUT NEUROAID ▸ CLINIcal studies ▸ safety profile ▸ Medical Professionals
composition & dosage ▸ Find out if neuroaid is right for you ABOUT NeuroAiD is an oral treatment helping victims of strokes and traumatic brain injuries who suffer from established deficits to recover their functional independence in addition to rehabilitation therapies and exercises. Understanding Long-Term Bleeding Risk After Ischaemic Stroke in Young Adults

📰🧠🔬 STROKE STUDY HIGHLIGHTS – Antithrombotic Therapy and Bleeding Risk Among Young Adults After Ischemic Stroke by Rasing A, et al.

This study followed 1,226 adults aged 18-49 after a first ischaemic stroke to assess bleeding during antithrombotic treatment. The median follow-up was 4.2 years.

𝗪𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝗯𝗹𝗲𝗲𝗱𝗶𝗻𝗴 𝗮𝗺𝗼𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗮𝗱𝘂𝗹𝘁𝘀 𝗿𝗲𝗰𝗲𝗶𝘃𝗶𝗻𝗴 𝗮𝗻𝘁𝗶𝘁𝗵𝗿𝗼𝗺𝗯𝗼𝘁𝗶𝗰 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗳𝘁𝗲𝗿 𝗮𝗻 𝗶𝘀𝗰𝗵𝗮𝗲𝗺𝗶𝗰 𝘀𝘁𝗿𝗼𝗸𝗲?

𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀
The estimated five-year risk of bleeding requiring medical attention was 10.7%.
Women, patients with cardioembolic stroke and those receiving anticoagulants had higher bleeding risks.
Women’s increased risk was mainly explained by gynaecological bleeding.
Most bleeding events were minor; nine were major, with no bleeding-related deaths.

𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀
These findings indicate that young stroke survivors receiving antiplatelet or anticoagulant therapy face a substantial long-term risk of bleeding, which should be considered when evaluating the risks and benefits of long-term antithrombotic therapy.

📄 Access the full article at: Rasing A, Verburgt E, Ekker MS, et al. Antithrombotic Therapy and Bleeding Risk Among Young Adults After Ischemic Stroke. JAMA Netw Open. 2026;9(9): e2635826. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854434?__cf_chl_rt_tk=ECSaKlNHaWJClvjwq_U3r6GCi4qTP2DsNqh6wUmno5A-1794290433-1.0.1.1-0qqFmPmkyEkNVmo64jskK_50hY70_F5CgeSlxj2Es3Y. This is an open-access article under a CC BY 4.0 license.